Search Results Search Sort by RelevanceMost Recent Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care. Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. Case and Commentary Jul 2019 Should Aggregate Patient Preference Data Be Used to Make Decisions on Behalf of Unrepresented Patients? Nathaniel Sharadin, PhD, MA Ethical and practical problems with preference modeling can undermine how reliably predictors can be used in high-stakes decisions. AMA J Ethics. 2019;21(7):E566-574. doi: 10.1001/amajethics.2019.566. AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600. Podcast Feb 2022 Author Interview: “How Should Clinicians Determine a Traumatized Patient’s Readiness to Return to Work?” Tabitha E. H. Moses, MS joins Ethics Talk to discuss her article, coauthored with Dr Arash Javanbakht: “How Should Clinicians Determine a Traumatized Patient’s Readiness to Return to Work?” Case and Commentary May 2022 Should Clinicians Prescribe Non-FDA Regulated Dietary Supplements When Caring for Children With Hypovitaminosis D? Ethan A. Mezoff, MD, Hannah Hays, MD, and Ala Shaikhkhalil, MD Children with micronutrient deficiency might need supplementation, sometimes in irregularly high doses. AMA J Ethics. 2022;24(5):E353-360. doi: 10.1001/amajethics.2022.353. Case and Commentary May 2022 How Does Cognitive Bias Affect Conversations With Patients About Dietary Supplements? Ila M. Harris, PharmD, Christine C. Danner, PhD, and David J. Satin, MD Some allopathic clinicians’ biases influence the information they draw upon to make decisions and offer recommendations. AMA J Ethics. 2022;24(5):E368-375. doi: 10.1001/amajethics.2022.368. Policy Forum May 2022 Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention? Amy B. Cadwallader, PhD and AMA Council on Science and Public Health Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients. AMA J Ethics. 2022;24(5):E410-418. doi: 10.1001/amajethics.2022.410. Case and Commentary Jun 2022 Should Children Be Enrolled in Clinical Research in Conflict Zones? Dónal O’Mathúna, PhD and Nawaraj Upadhaya, PhD Research that places subjects and investigators at risk of additional harm must be considered carefully. AMA J Ethics. 2022;24(6):E463-471. doi: 10.1001/amajethics.2022.463. Pagination Current page 1 Page 2 Page 3 Page 4 Next page Next › Last page Last »
Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care.
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.
Case and Commentary Jul 2019 Should Aggregate Patient Preference Data Be Used to Make Decisions on Behalf of Unrepresented Patients? Nathaniel Sharadin, PhD, MA Ethical and practical problems with preference modeling can undermine how reliably predictors can be used in high-stakes decisions. AMA J Ethics. 2019;21(7):E566-574. doi: 10.1001/amajethics.2019.566.
AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600.
Podcast Feb 2022 Author Interview: “How Should Clinicians Determine a Traumatized Patient’s Readiness to Return to Work?” Tabitha E. H. Moses, MS joins Ethics Talk to discuss her article, coauthored with Dr Arash Javanbakht: “How Should Clinicians Determine a Traumatized Patient’s Readiness to Return to Work?”
Case and Commentary May 2022 Should Clinicians Prescribe Non-FDA Regulated Dietary Supplements When Caring for Children With Hypovitaminosis D? Ethan A. Mezoff, MD, Hannah Hays, MD, and Ala Shaikhkhalil, MD Children with micronutrient deficiency might need supplementation, sometimes in irregularly high doses. AMA J Ethics. 2022;24(5):E353-360. doi: 10.1001/amajethics.2022.353.
Case and Commentary May 2022 How Does Cognitive Bias Affect Conversations With Patients About Dietary Supplements? Ila M. Harris, PharmD, Christine C. Danner, PhD, and David J. Satin, MD Some allopathic clinicians’ biases influence the information they draw upon to make decisions and offer recommendations. AMA J Ethics. 2022;24(5):E368-375. doi: 10.1001/amajethics.2022.368.
Policy Forum May 2022 Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention? Amy B. Cadwallader, PhD and AMA Council on Science and Public Health Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients. AMA J Ethics. 2022;24(5):E410-418. doi: 10.1001/amajethics.2022.410.
Case and Commentary Jun 2022 Should Children Be Enrolled in Clinical Research in Conflict Zones? Dónal O’Mathúna, PhD and Nawaraj Upadhaya, PhD Research that places subjects and investigators at risk of additional harm must be considered carefully. AMA J Ethics. 2022;24(6):E463-471. doi: 10.1001/amajethics.2022.463.